Table 12 Performance comparison (f1-score and accuracy) with the RF method, based on the second study with 450k DNA methylation profile dataset
Cancer type | Method | F1-score | Accuracy |
|---|---|---|---|
Breast Cancer (BRCA) | RF (Modhukur et al.) | 0.954 | 0.926 |
Proposed method | 0.986 | 0.986 | |
Colon Cancer (COAD) | RF (Modhukur et al.) | 0.987 | 0.980 |
Proposed method | 0.988 | 0.989 | |
Kidney Cancer (KIRC) | RF (Modhukur et al.) | 0.987 | 0.993 |
Proposed method | 0.99 | 0.989 | |
Liver Cancer (LIHC) | RF (Modhukur et al.) | 0.99 | 0.99 |
Proposed method | 1.0 | 1.0 | |
Lung Cancer (LUSC) | RF (Modhukur et al.) | 0.931 | 0.951 |
Proposed method | 0.99 | 0.986 | |
Prostate Cancer (PRAD) | RF (Modhukur et al.) | 0.98 | 0.98 |
Proposed method | 0.99 | 0.98 | |
Thyroid Cancer (THCA) | RF (Modhukur et al.) | 1.00 | 0.99 |
Proposed method | 0.98 | 0.99 |